• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

司来吉兰对甲基苯丙胺所致多巴胺耗竭的影响。

The effects of deprenyl on methamphetamine-induced dopamine depletions.

作者信息

Johnson S K, Medina D, Wagner G C

机构信息

Department of Psychology, Rutgers University, New Brunswick, NJ.

出版信息

J Neural Transm Gen Sect. 1992;89(1-2):123-7. doi: 10.1007/BF01245358.

DOI:10.1007/BF01245358
PMID:1418863
Abstract

The effects of deprenyl on methamphetamine-induced dopamine depletions were studied in mice. Four SC injections of 12.5 mg/kg of methamphetamine at two-hour intervals caused substantial (72-82%) and long-lasting depletions of striatal dopamine. Pretreatment with either 25 or 40 mg/kg of deprenyl did not significantly alter the magnitude of this depletion. These results indicate that, unlike what is observed following MPTP, there is no protection afforded dopaminergic cells by deprenyl pretreatment in the methamphetamine model of parkinsonism.

摘要

在小鼠中研究了司来吉兰对甲基苯丙胺诱导的多巴胺耗竭的影响。每隔两小时皮下注射4次12.5mg/kg的甲基苯丙胺,可导致纹状体多巴胺大量(72 - 82%)且持久的耗竭。用25mg/kg或40mg/kg的司来吉兰预处理并未显著改变这种耗竭的程度。这些结果表明,与1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP)处理后观察到的情况不同,在帕金森病的甲基苯丙胺模型中,司来吉兰预处理对多巴胺能细胞没有保护作用。

相似文献

1
The effects of deprenyl on methamphetamine-induced dopamine depletions.司来吉兰对甲基苯丙胺所致多巴胺耗竭的影响。
J Neural Transm Gen Sect. 1992;89(1-2):123-7. doi: 10.1007/BF01245358.
2
Chronic L-deprenyl does not alter the restoration of striatal dopamine in MPTP-lesioned mice.
J Neurosci Res. 1989 Jul;23(3):326-9. doi: 10.1002/jnr.490230312.
3
Biphasic effects of selegiline on striatal dopamine: lack of effect on methamphetamine-induced dopamine depletion.司来吉兰对纹状体多巴胺的双相效应:对甲基苯丙胺诱导的多巴胺耗竭无影响。
Neurochem Res. 2001 Jan;26(1):65-74. doi: 10.1023/a:1007632700126.
4
Novel sites of action for deprenyl in MPTP-parkinsonism: metabolite-mediated protection against striatal neurotoxicity and suppression of MPTP-induced increase of dopamine turnover in C57BL mice.司来吉兰在MPTP诱导的帕金森病中的新作用位点:代谢物介导的对纹状体神经毒性的保护作用以及对C57小鼠中MPTP诱导的多巴胺周转率增加的抑制作用。
Prog Brain Res. 1995;106:155-71. doi: 10.1016/s0079-6123(08)61212-1.
5
Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition.多次小剂量给予(-)司来吉兰可增强大脑中的儿茶酚胺能活性并降低5-羟色胺能活性,且这些作用与单胺氧化酶-B抑制无关。
Arch Int Pharmacodyn Ther. 1994 Jul-Aug;328(1):1-15.
6
Effects of L-deprenyl and amantadine in an MPTP-model of parkinsonism.
J Neural Transm Suppl. 1990;32:269-75. doi: 10.1007/978-3-7091-9113-2_37.
7
Norepinephrine loss exacerbates methamphetamine-induced striatal dopamine depletion in mice.去甲肾上腺素缺失会加剧甲基苯丙胺诱导的小鼠纹状体多巴胺耗竭。
Eur J Pharmacol. 1995 Sep 5;283(1-3):99-102. doi: 10.1016/0014-2999(95)00313-a.
8
Differential effects of L-deprenyl on MPP+- and MPTP-induced dopamine overflow in microdialysates of striatum and nucleus accumbens.L-司来吉兰对纹状体和伏隔核微透析液中MPP⁺和MPTP诱导的多巴胺溢出的不同影响。
Life Sci. 2000 Jun 8;67(3):241-50. doi: 10.1016/s0024-3205(00)00628-7.
9
Sexual differences and estrous cycle in methamphetamine-induced dopamine and serotonin depletions in the striatum of mice.甲基苯丙胺诱导的小鼠纹状体多巴胺和5-羟色胺耗竭中的性别差异与发情周期
J Neural Transm (Vienna). 2000;107(4):419-27. doi: 10.1007/s007020070084.
10
Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons.司来吉兰(丙炔苯丙胺),一种具有活性代谢产物的选择性单胺氧化酶-B抑制剂;对运动活性、多巴胺能神经传递及黑质多巴胺能神经元放电频率的影响。
J Pharmacol Exp Ther. 1991 Nov;259(2):841-7.

引用本文的文献

1
Biphasic effects of selegiline on striatal dopamine: lack of effect on methamphetamine-induced dopamine depletion.司来吉兰对纹状体多巴胺的双相效应:对甲基苯丙胺诱导的多巴胺耗竭无影响。
Neurochem Res. 2001 Jan;26(1):65-74. doi: 10.1023/a:1007632700126.
2
Sexual differences in sensitivity to methamphetamine toxicity.对甲基苯丙胺毒性敏感性的性别差异。
J Neural Transm Gen Sect. 1993;93(1):67-70. doi: 10.1007/BF01244939.

本文引用的文献

1
Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys.帕吉林和司来吉兰可预防1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP)对猴子的神经毒性。
Eur J Pharmacol. 1984 Oct 30;106(1):209-10. doi: 10.1016/0014-2999(84)90700-3.
2
Deprenyl (selegiline) in combination treatment of Parkinson's disease.
Acta Neurol Scand Suppl. 1983;95:123-6. doi: 10.1111/j.1600-0404.1983.tb01526.x.
3
Clinical evaluation of deprenyl (selegiline) in the treatment of Parkinson's disease.司来吉兰(丙炔苯丙胺)治疗帕金森病的临床评估。
Acta Neurol Scand Suppl. 1983;95:117-22. doi: 10.1111/j.1600-0404.1983.tb01525.x.
4
Deprenyl (selegiline) in the treatment of Parkinson's disease.司来吉兰治疗帕金森病
Acta Neurol Scand Suppl. 1983;95:103-5. doi: 10.1111/j.1600-0404.1983.tb01522.x.
5
Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors.单胺氧化酶抑制剂对1-甲基-4-苯基-1,2,5,6-四氢吡啶多巴胺能神经毒性的保护作用。
Nature. 1984;311(5985):467-9. doi: 10.1038/311467a0.
6
Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study.
J Neural Transm. 1985;64(2):113-27. doi: 10.1007/BF01245973.
7
Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease.司来吉兰治疗晚期帕金森病症状波动
Clin Neuropharmacol. 1988 Feb;11(1):45-55. doi: 10.1097/00002826-198802000-00004.
8
Methamphetamine-induced neuronal damage: a possible role for free radicals.甲基苯丙胺诱导的神经元损伤:自由基的潜在作用。
Neuropharmacology. 1989 Oct;28(10):1145-50. doi: 10.1016/0028-3908(89)90130-5.
9
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.
Science. 1989 Aug 4;245(4917):519-22. doi: 10.1126/science.2502843.
10
Evaluation of the effects of inhibition of monoamine oxidase and senescence on methamphetamine-induced neuronal damage.单胺氧化酶抑制和衰老对甲基苯丙胺诱导的神经元损伤影响的评估。
Int J Dev Neurosci. 1991;9(2):171-4. doi: 10.1016/0736-5748(91)90008-a.